# Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Study · id `cardio:ct-nct01676220` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01676220](<https://clinicaltrials.gov/study/NCT01676220>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01676220

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 878 participants.

## Technical summary

Registry record NCT01676220. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2015-04-23.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 878 participants (enrolled count; ClinicalTrials.gov record NCT01676220, source copy `cardio:ctgov-nct01676220-2015-06-24`, retrieved 2026-10-26)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01676220, source copy `cardio:ctgov-nct01676220-2015-06-24`, retrieved 2026-10-26)
- Primary completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01676220, source copy `cardio:ctgov-nct01676220-2015-06-24`, retrieved 2026-10-26)
- Completion: 2014-03 (actual) (ClinicalTrials.gov record NCT01676220, source copy `cardio:ctgov-nct01676220-2015-06-24`, retrieved 2026-10-26)
- Results first posted: 2015-04-23 (ClinicalTrials.gov record NCT01676220, source copy `cardio:ctgov-nct01676220-2015-06-24`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Canada; Czechia; Denmark; Estonia; Finland; Hungary; Japan; Latvia; Lithuania; Netherlands; Puerto Rico; Romania; Slovakia; Sweden (ClinicalTrials.gov record NCT01676220, source copy `cardio:ctgov-nct01676220-2015-06-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01676220-2015-06-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
- Acronym: EDITION III
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): HOE901-U300 (new formulation of insulin glargine)
- Intervention (Drug): Lantus (insulin glargine)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) (`cardio:pubmed-25641260`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d26dc73a56373128f1ca54ecdd6386653f2711eb14106e8f28dc6c49ee25379b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
